Moxifloxacin five-day therapy versus placebo in acute bacterial rhinosinusitis

Laryngoscope

Volumn 120, Issue 5, 2010, Pages 1057-1062

  Hadley, James A ^a   Mösges, Ralph ^b   Desrosiers, Martin ^c   Haverstock, Daniel ^d   Van Veenhuyzen, David ^d   Herman Gnjidic, Zeljka ^e  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d BAYER CORPORATION   (United States)

^e Bayer HealthCare Pharmaceuticals   (Canada)

Author keywords

Acute bacterial rhinosinusitis; Moxifloxacin; Placebo controlled trial

Indexed keywords

ANTIHISTAMINIC AGENT; CLARITHROMYCIN; CORTICOSTEROID; DECONGESTIVE AGENT; MOXIFLOXACIN; NOSE SPRAY; OXACILLIN; PENICILLIN G; PLACEBO;

ACUTE BACTERIAL RHINOSINUSITIS; ADULT; ARTICLE; BACTERIUM CULTURE; BURNING SENSATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROORGANISM DETECTION; MORAXELLA CATARRHALIS; MULTICENTER STUDY; PATIENT ASSESSMENT; PHASE 3 CLINICAL TRIAL; POPULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOSINUSITIS; SCORING SYSTEM; SINO NASAL OUTCOME TEST 16; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; THERAPY EFFECT; TOOTH ABSCESS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77951707032     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.20878     Document Type: Article

References (23)

1. Ahovuo-Saloranta A, Borisenko OV, Kovanen N, et al. Antibiotics for acute maxillary sinusitis. Cochrane Database Syst Rev 2008:CD000243.
2. Desrosiers M, Klossek JM, Benninger M. Management of acute bacterial rhinosinusitis; current issues and future perspectives. Int J Clin Pract 2006;60:190-200. (Pubitemid 43740499)
3. Anon JB, Jacobs MR, Poole MD, et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004;130:1-45. (Pubitemid 38120257)
4. Klossek JM, Federspil P. Update on treatment guidelines for acute bacterial sinusitis. Int J Clin Pract 2005;59:230-238. (Pubitemid 40331226)
5. Ambrose PG, Anon JB, Bhavnani SM, et al. Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis. Diagn Microbiol Infect Dis 2008;61:13-20. (Pubitemid 351509752)
6. Falagas ME, Karageorgopoulos DE, Grammatikos AP, Matthaiou DK. Effectiveness and safety of short vs. long duration of antibiotic therapy for acute bacterial sinusitis: a meta-analysis of randomized trials. Br J Clin Pharmacol 2009;67:161-171.
7. Ariza H, Rojas R, Johnson P, et al. Eradication of common pathogens at days 2, 3 and 4 of moxifloxacin therapy in patients with acute bacterial sinusitis. BMC Ear Nose Throat Disord 2006;6:8. (Pubitemid 44064112)
8. Anzai Y, Jarvik JG, Sullivan SD, Hollingworth W. The cost-effectiveness of the management of acute sinusitis. Am J Rhinol 2007;21:444-451.
9. Gehanno P, Darantiere S, Dubreuil C, et al. A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus. J Antimicrob Chemother 2002;49:821-826.
10. Brueggemann AB, Kugler KC, Doern GV. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother 1997;41:1594-1597.
11. Brook I. Microbiology and antimicrobial management of sinusitis. J Laryngol Otol 2005;119:251-258.
12. Siegert R, Gehanno P, Nikolaidis P, et al. A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. Respir Med 2000;94:337-344. (Pubitemid 30323568)
13. Rakkar S, Roberts K, Towe BF, Flores SM, Heyd A, Warner J. Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience. Int J Clin Pract 2001;55:309-315. (Pubitemid 32605792)
14. Burke T, Villanueva C, Mariano H Jr, et al. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Clin Ther 1999;21:1664-1677. (Pubitemid 29523362)
15. Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004;130:S1-S45.
16. Scheid DC, Hamm RM. Acute bacterial rhinosinusitis in adults: part II. Treatment. Am Fam Physician 2004;70:1697-1704.
17. Nolen TM. Sedative effects of antihistamines: safety, performance, learning, and quality of life. Clin Ther 1997;19:39-55.
18. Salerno SM, Jackson JL, Berbano EP. The impact of oral phenylpropanolamine on blood pressure: a meta-analysis and review of the literature. J Hum Hypertens 2005;19:643-652. (Pubitemid 41131666)
19. Guidance for Industry. Acute Bacterial Sinusitis Developing Drugs for Treatment, US Department of Health and Human Service, FDA, CDER October 2007, Revision 1. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070939.pdf. Accessed February 24, 2010.
20. Desrosiers M, Frenkiel S, Hamid QA, et al. Acute bacterial sinusitis in adults: management in the primary care setting. J Otolaryngol 2002;31:S31-S42.
21. National Institutes of Health and Clinical Excellence. Sinusitus-management. Available at: http://cks.library.nhs.uk/sinusitis/ management/quick-answers/scenario-acute-sinusitis/prescribing-antibiotics#- 369932. Accessed February 24, 2010.
22. Agence Française de Sécurité Sanitaire des Produite de Santé . Antibiotherapie par voie generale en practique courante: sinusitis aigue de l'adulte; 2005. Available at: http://www.afssaps.sante.fr/ pdf/5/sinu-ad.pdf. Accessed June 2009.
23. Agence Française de Sécurité Sanitaire des Produite de Santé. Antibiotherapie par voie generale en practique courante: sinusitis aigue de l'adulte; 2005. Available at: http://www.afssaps.fr/Infos-de- securite/Recommandationsde-bonne-pratique/Antibiotherapie-par-voie-generale- dansles-infections-respiratoires-recommandations-de-bonnespratique/ %28language%29/fre-FR. Accessed February 24, 2010.